The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

Summary

This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).

Timeline

Start

2025-05-31

Primary completion

2026-09-30

Completion

2026-12-31

Drugs

Indications